A D Thornton1, P Ravn, M Winslet, K Chester. 1. Department of Oncology, Royal Free and University College School of Medicine, University College London, London, UK.
Abstract
BACKGROUND: Bevacizumab is an angiogenesis inhibitor and a new therapy for the treatment of colorectal cancer. It is a humanized monoclonal antibody that targets vascular endothelial growth factor. METHODS: This review is based on a literature search of Medline, Pubmed, ISI web of knowledge and other published work for original articles, reviews and abstracts relevant to the surgical management of colorectal cancer with bevacizumab. RESULTS AND CONCLUSION: Combined with current chemotherapy regimens, bevacizumab offers a significant survival advantage, making it likely to see widespread use. Despite being generally well tolerated, serious toxicities, including wound complications and gastrointestinal perforation, have been reported that affect surgical management. Consideration should be given to the timing of surgical and adjuvant intervention when using this drug.
BACKGROUND:Bevacizumab is an angiogenesis inhibitor and a new therapy for the treatment of colorectal cancer. It is a humanized monoclonal antibody that targets vascular endothelial growth factor. METHODS: This review is based on a literature search of Medline, Pubmed, ISI web of knowledge and other published work for original articles, reviews and abstracts relevant to the surgical management of colorectal cancer with bevacizumab. RESULTS AND CONCLUSION: Combined with current chemotherapy regimens, bevacizumab offers a significant survival advantage, making it likely to see widespread use. Despite being generally well tolerated, serious toxicities, including wound complications and gastrointestinal perforation, have been reported that affect surgical management. Consideration should be given to the timing of surgical and adjuvant intervention when using this drug.
Authors: Efstathios T Pavlidis; Konstantinos D Ballas; Nikolaos G Symeonidis; Kyriakos Psarras; Georgios Koliakos; Kokona Kouzi-Koliakos; Konstantina Topouridou; Savas F Rafailidis; Theodoros E Pavlidis; Georgios N Marakis; Athanasios K Sakantamis Journal: Int J Colorectal Dis Date: 2010-08-06 Impact factor: 2.571
Authors: Joseph P Erinjeri; Abigail J Fong; Nancy E Kemeny; Karen T Brown; George I Getrajdman; Stephen B Solomon Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Sung Chul Lim; Hoon Cho; Tae Bum Lee; Cheol Hee Choi; Young Don Min; Sung Soo Kim; Kyung Jong Kim Journal: Yonsei Med J Date: 2010-09 Impact factor: 2.759
Authors: John Christoforidis; Robert Ricketts; Cedric Pratt; Jordan Pierce; Scott Bean; Michael Wells; Xiaoli Zhang; Krista La Perle Journal: Clin Ophthalmol Date: 2012-01-10